


VOLUME 99 OCTOBER 2018

NUMBER 4 SUPPLEMENT

SIXTY-SEVENTH **ANNUAL MEETING** Sheraton New Orleans and New Orleans Marriott | New Orleans, LA USA

October 28 - November 1, 2018

"There will be epidemics..."



Supplement to The American Journal of Tropical Medicine and Hygiene

Sponsored Symposium

From R&D to Access for Sleeping Sickness Elimination: Innovative Public-Private Partnerships for New Tools

Sponsored by Sanofi and Drugs for Neglected Diseases initiative (DNDi)

Sheraton - Waterbury (2nd Floor) Monday, October 29, 7:15 p.m. - 9:15 p.m.

The first all-oral treatment for *Trypanosoma brucei gambiense* human African trypanosomiasis (g-HAT), co-developed through an innovative public-private partnership between Sanofi and the Drugs for Neglected Diseases *initiative* (DND*i*) has proven to be effective and safe, according to results of clinical trials led by DND*i* and numerous partners in DR Congo and Central African Republic, and published in *The Lancet* in October 2017. This new drug joins new diagnostics to round out the elimination toolbox for this fatal disease that is now at a historical low in terms of global disease burden.

CO-CHAIR

Victor Kande Betu Kumeso

NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo

Luc Kuykens Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

SESSION INTRODUCTION

Victor Kande Betu Kumeso NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo

DISCUSSION FACILITATION

Luc Kuykens Senior Vice President Global Health Programs, Sanofi, Gentilly, France

AN ALTERNATIVE MODEL FOR DRUG DEVELOPMENT: THE STORY OF FEXINIDAZOLE

Nathalie Strub-Wourgaft Clinical Director, Drugs for Neglected Diseases initiative, Geneva, Switzerland

WORKING IN PARTNERSHIP FOR SLEEPING SICKNESS ELIMINATION: USING NEW TECHNOLOGIES

Erick Mwamba Miaka Director, National HAT Programme, Kinshasa, Democratic Republic of the Congo

FINDING EVERY LAST CASE: THE ROLE OF DIAGNOSTICS IN HAT ELIMINATION

Veerle Lejon Research Director, Institut de Recherche pour le Développement, Montpellier, France

ROLL-OUT OF ALL-ORAL TREATMENT: INTRODUCING A DONATION PROGRAM FOR SLEEPING SICKNESS

Luc Kuykens Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

STRIVING TOWARDS HAT ELIMINATION IN SOUTH SUDAN: AN OPERATIONAL PERSPECTIVE

Laurence Flévaud Operational Centre Barcelona-Athens, Médecins Sans Frontières

MONITORING HAT ELIMINATION: PLANS FOR VALIDATION

Gerardo Priotto Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland